Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111In-DOTA-daratumumab
- Development stage
- Unknown
- Lead developer
- City of Hope Medical Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
111In-DOTA-daratumumab is a radiolabeled monoclonal antibody used as a diagnostic imaging agent in the management of multiple myeloma. It consists of the anti-CD38 monoclonal antibody daratumumab conjugated to the chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), which coordinates the gamma-emitting radioisotope indium-111. In clinical settings, it is primarily utilized for SPECT (Single Photon Emission Computed Tomography) imaging to evaluate the biodistribution, pharmacokinetics, and organ dosimetry of daratumumab-based therapies. It often serves as a companion diagnostic for alpha-emitting therapeutic radiopharmaceuticals, such as 225Ac-DOTA-daratumumab, in a theranostic approach to treat relapsed or refractory plasma cell malignancies.
- Other names
- indium In 111-DOTA-daratumumab111In-daratumumab
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on 111In-DOTA-daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 111In-DOTA-daratumumab.